What is Xaira Therapeutics?
AI-native drug discovery company founded with more than $1 billion in committed capital.
- Category
- AI drug discovery
- Headquarters
- South San Francisco, California
- Founded
- 2024
- Employees
- Private; large launch-stage biotech team
- Total funding
- More than $1 billion committed at launch
- Status
- Private
What is Xaira Therapeutics?
Xaira Therapeutics is a ai drug discovery company headquartered in South San Francisco, California.
Xaira combines AI research, biological data generation, and drug-development capabilities to create therapeutics across disease areas. The company launched with support from ARCH Venture Partners, Foresite Labs, F-Prime, NEA, Sequoia, and other life-sciences investors.
The company was founded in 2024 and remains private. Its public profile is strongest around AI drug discovery platform and Therapeutic pipeline, while detailed revenue figures are not publicly disclosed.
As of June 2026, the safest public read is that Xaira Therapeutics is scaling through enterprise partnerships and capital-intensive product development rather than a self-serve consumer motion.
What does Xaira Therapeutics offer?
Xaira Therapeutics's public product set centers on AI drug discovery platform, Therapeutic pipeline, Biological data generation.
- AI drug discovery platform· AI biology
- Therapeutic pipeline· Drug development
- Biological data generation· Data platform
- Translational medicine· R&D
Sources:Xaira website
How does Xaira Therapeutics make money?
Pipeline biotech model: value comes from internal programs, partnerships, and future clinical milestones; no software pricing is public.
Pipeline biotech model: value comes from internal programs, partnerships, and future clinical milestones; no software pricing is public. No public product pricing; drug-development company.
Growth is driven by enterprise adoption, strategic partnerships, and proof that the platform can deliver measurable operational, clinical, scientific, or mission outcomes. Because Xaira Therapeutics does not publish standard list prices, buyers should treat budget sizing as a custom-contract exercise.
The commercial motion therefore depends on executive sponsorship, security and compliance review, and evidence that the product can integrate into existing workflows rather than replace them all at once.
Who leads Xaira Therapeutics?
Xaira Therapeutics is led by Marc Tessier-Lavigne, CEO.
- Marc Tessier-LavigneCEOCEO · since 2024Neuroscientist and former Stanford president leading the company.
- David BakerCo-founder / scientific advisorFounder networkProtein-design scientist involved in the launch consortium.
- Arvind RajpalExecutive chairman / investorLaunch leadershipLife-sciences investor involved through Foresite Labs.
How do you contact Xaira Therapeutics's leadership?
Public contact form; no verified personal email pattern found. Use the listed public company route rather than guessed personal inboxes.
Public contact form; no verified personal email pattern foundSources:Xaira website
How much funding has Xaira Therapeutics raised?
Xaira Therapeutics has more than $1 billion committed at launch and is private.
2024: Launch financing — More than $1 billion, led/backed by ARCH, Foresite Labs, F-Prime, NEA, Sequoia and others (Valuation undisclosed).
The latest public valuation/status marker is Undisclosed. Where a valuation is undisclosed, public reporting only supports the financing amount and participating investors.
Funding is best interpreted as capacity for product build-out, hiring, regulatory or deployment work, and longer sales cycles; it should not be read as proof of profitability unless the company has separately disclosed profitability.
How did Xaira Therapeutics get here?
Xaira Therapeutics's timeline runs from its 2024 founding through major financing and product milestones.
- 2024Company launchedXaira launched with over $1 billion in committed capital.
- 2024Leadership announcedMarc Tessier-Lavigne became CEO.
- 2024AI-biology thesis setThe company positioned itself around large-scale AI and biological data.
- 2025Hiring and platform build-outXaira continued building a South San Francisco team.
- 2026Pipeline developmentThe company remained private with programs not fully disclosed.
Who are Xaira Therapeutics's competitors?
Xaira Therapeutics competes with specialized startups and larger platform companies in ai drug discovery.
Xaira Therapeutics — frequently asked questions
